Key facts: Johnson & Johnson halts JNJ-5939 trial for atopic dermatitis; drug shows good tolerability
I'm PortAI, I can summarize articles.
Johnson & Johnson has stopped its phase 2b trial of JNJ-5939 for atopic dermatitis due to insufficient efficacy. The company is still pursuing other treatments for the condition.12Johnson & Johnson reported that its drug JNJ-5939 demonstrated good tolerability in a Phase 2B Duplex-AD proof-of-concept study.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments